Cencora, Inc. (COR)
NYSE:COR
Want to see COR full AI Analyst Report?
COR Stock Chart & Stats
$327.56
$2.86(1.22%)
At close: 4:00 PM EST
$327.56
$2.86(1.22%)
Day’s Range― - ―
52-Week Range$244.82 - $377.54
Previous CloseN/A
Volume440.68K
Average Volume (3M)2.04M
Market Cap
$53.49B
Enterprise Value$63.64B
Total Cash (Recent Filing)$2.24B
Total Debt (Recent Filing)$12.39B
Price to Earnings (P/E)9.3
Beta0.08
Next Earnings
Aug 05, 2026EPS Estimate
4.36Next Dividend Ex-DateN/A
Dividend Yield0.66%
Share Statistics
EPS (TTM)13.12
Shares Outstanding194,561,070
10 Day Avg. Volume2,255,803
30 Day Avg. Volume2,039,038
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda15.53
Forecast
1Y Price Target
$358.40Price Target Upside9.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)17.76
Revenue Forecast (FY)$338.30B
Bulls Say, Bears Say
Bulls Say
Guidance CredibilityAnalyst interprets management's conservative guidance as consistent with historical guidance philosophy, implying potential upside to earnings forecasts if results track past conservative patterns.
Industry Fundamentals And ValuationAnalyst highlights stabilized generic pricing, removal of major litigation risks, and reduced drug pricing uncertainty, supporting a higher valuation for the distributor group and stronger long-term earnings prospects.
Oncology AcquisitionAcquiring full ownership of OneOncology reorients the portfolio toward higher-growth oncology services and is expected to add incremental adjusted operating income to the US Healthcare segment, supporting consolidated earnings.
Bears Say
Client Concentration RiskHeavy reliance on a major client creates concentration risk where store closures or contract changes could materially reduce revenue visibility and undermine investor confidence.
Near-term Growth SlowdownShare price weakness followed a slowdown in US Healthcare segment growth, signaling investor concern about near-term performance and potential pressure on stock momentum.
Regulatory OverhangRegulatory uncertainty created an investor overhang that suppressed interest in the stock until those issues were addressed, leaving sensitivity to any future regulatory developments.
Cencora News
COR FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was $244.82 and its highest was $377.54 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is $53.49B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 70 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on May 06, 2026. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.818 by -$0.068.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.66%. See more information on Cencora, Inc. dividends here
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 4.36.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 194,561,070 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of $4.75 in its last earnings report, missing expectations of $4.818. Following the earnings report the stock price went down -17.378%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in COR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$358.40 (9.42% Upside)
$358.40 (9.42% Upside)
Blogger Sentiment
Bullish
COR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 75.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.52%
12-Months-Change
Fundamentals
Return on Equity
115.93%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong profitability and cash-generation metrics (EPS growth +7.5%, gross profit +16%, operating income +6%), a raised EPS range, improved operating income guidance, robust international performance, and the resumption of $1B share repurchases against material near-term revenue pressures (reduced consolidated revenue guidance from 7%–9% to 4%–6%) driven by WAC price reductions, account losses and faster mail-order brand conversions. Management highlighted transitory items (weather, COVID vaccine comparisons) and acquisition-related expense impacts but maintained confidence in long-term operating income growth and free cash flow generation.View all COR earnings summariesCOR Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
COR Stock 12 Month Forecast
Average Price Target
$358.40
▲(9.42% Upside)
Technical Analysis
Ownership Overview
0.35% Insiders
31.34% Mutual Funds
15.80% Other Institutional Investors
25.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---